4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $548,364.96 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 42,608 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96. Following the sale, the insider owned 899,877 shares of the company’s stock, valued at approximately $11,581,416.99. This represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $189,171.75.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $10.84 on Friday. The stock has a market cap of $566.72 million, a PE ratio of -4.22 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a one year low of $4.14 and a one year high of $14.00. The stock has a fifty day moving average of $10.34 and a 200 day moving average of $9.43.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on FDMT shares. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Chardan Capital reiterated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, The Goldman Sachs Group set a $33.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.88.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at approximately $39,000. Wexford Capital LP bought a new stake in 4D Molecular Therapeutics during the 3rd quarter worth approximately $41,000. AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $46,000. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC purchased a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $48,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.